389 related articles for article (PubMed ID: 38689664)
1. The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment.
Liu Y; Yu S; Chen Y; Hu Z; Fan L; Liang G
Front Pharmacol; 2024; 15():1376955. PubMed ID: 38689664
[TBL] [Abstract][Full Text] [Related]
2. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.
Ye Q; Lin Y; Li R; Wang H; Dong C
Semin Cancer Biol; 2022 Nov; 86(Pt 2):607-623. PubMed ID: 35339668
[TBL] [Abstract][Full Text] [Related]
3. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies.
Li J; Wang Q; Han Y; Jiang L; Lu S; Wang B; Qian W; Zhu M; Huang H; Qian P
J Hematol Oncol; 2023 Jun; 16(1):65. PubMed ID: 37353849
[TBL] [Abstract][Full Text] [Related]
4. Nanodrug Delivery Systems in Antitumor Immunotherapy.
Guo Z; Ye J; Cheng X; Wang T; Zhang Y; Yang K; Du S; Li P
Biomater Res; 2024; 28():0015. PubMed ID: 38840653
[TBL] [Abstract][Full Text] [Related]
5. Polymeric nanomedicines targeting hematological malignancies.
Gu W; Qu R; Meng F; Cornelissen JJLM; Zhong Z
J Control Release; 2021 Sep; 337():571-588. PubMed ID: 34364920
[TBL] [Abstract][Full Text] [Related]
6. Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood-brain barrier.
Wei Y; Xia X; Li H; Gao H
Expert Opin Drug Deliv; 2023; 20(12):1713-1730. PubMed ID: 37542516
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.
Shakil MS; Niloy MS; Mahmud KM; Kamal MA; Islam MA
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804818
[TBL] [Abstract][Full Text] [Related]
8. Perceptions and Misperceptions of Early Palliative Care Interventions for Patients With Hematologic Malignancies Undergoing Bone Marrow Transplantation.
Suthumphong C; Tran DB; Ruiz M
Cureus; 2021 Mar; 13(3):e13876. PubMed ID: 33868840
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
10. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
11. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
[TBL] [Abstract][Full Text] [Related]
12. Cell Membrane-Camouflaged Nanocarriers for Cancer Diagnostic and Therapeutic.
Li S; Liu J; Sun M; Wang J; Wang C; Sun Y
Front Pharmacol; 2020; 11():24. PubMed ID: 32116701
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-biomimetic nanosystems to improve antitumor effects of paclitaxel on epithelial cancers.
Song M; Dong S; An X; Zhang W; Shen N; Li Y; Guo C; Liu C; Li X; Chen S
J Control Release; 2022 May; 345():744-754. PubMed ID: 35381274
[TBL] [Abstract][Full Text] [Related]
15. Metformin as a therapeutic tool for resistant hematological malignancies: a literature review.
Paz GS; Fernandes J
Chin Clin Oncol; 2024 May; ():. PubMed ID: 38859606
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M; Khodakarami A; Ahmadi A; Fathi M; Gholizadeh Navashenaq J; Mohammadi H; Yousefi M; Hojjat-Farsangi M; Movasaghpour Akbari AA; Jadidi-Niaragh F
Expert Opin Ther Targets; 2022 Dec; 26(12):1057-1071. PubMed ID: 36683579
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in nanocarrier-based drug delivery systems for antitumour metastasis.
Peng S; Yuan X; Li H; Wei Y; Zhou B; Ding G; Bai J
Eur J Med Chem; 2023 Apr; 252():115259. PubMed ID: 36934485
[TBL] [Abstract][Full Text] [Related]
19. Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy.
Fan L; Wei A; Gao Z; Mu X
Biomed Pharmacother; 2023 May; 161():114451. PubMed ID: 36870279
[TBL] [Abstract][Full Text] [Related]
20. [Research Progress on the Influence of Tumor Extracellular Matrix Mechanic Properties on Nanodrug Delivery].
Zhao T; Wu H; Chen S; Wang J; Liu Y; Li T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 55(1):13-18. PubMed ID: 38322528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
